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Abstract
Background: Butyrate is an energy source for colonocytes that is formed by bacterial fermentation of dietary fiber
in the colon and that exerts broad anti-inflammatory activities. Although the administration of butyrate improves
homeostasis in patients and ameliorates IBD (Inflammatory Bowel Disease)-related lesions and symptoms, the
anti-inflammatory mechanisms of butyrate still remain unclear. To explore the impact of butyrate on Treg
(Regulatory T cell)/Th17 (T helper 17 cell) differentiation and colitis in rats.
Methods: The effect of butyrate on the expression of markers related to both Tregs and Th17 cells were determined
in human monocytes as well as a rat model of colitis induced by 2,4,6-trinitrobenzene sulfonic acid. Rats were treated
with butyrate in vivo, whereas the rat splenocytes and human monocytes were treated in vitro.
Results: We found that butyrate administration increased peripheral blood Treg cell levels as well as plasma levels of
anti-Th17 cytokines (IL-10 and IL-12). Butyrate administration further suppressed IL-17 levels in both plasma and colonic
mucosa, and ameliorated colonic colitis lesions in rats. This promotion of Treg activity and inhibition of IL-17 release
was also observed in human venous monocytes and rat splenocytes in vitro.
Conclusions: Our results suggest that butyrate plays a key role in regulating the Treg/Th17 balance and ultimately
protects the colon mucosa against the development of IBD.
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Background
Inflammatory bowel disease (IBD) consists of a group of
disorders characterized by recurrent inflammation in the
gastrointestinal tract. The two most common forms of
IBD are ulcerative colitis (UC) and Crohn’s disease (CD).
While the etiology of IBD remains uncertain, it has been
hypothesized that an undesired intestinal mucosal immune
response to luminal contents contributes to the onset of
IBD in a genetically predisposed patient [1].
CD4+ T helper (Th) cells regulate immunity and in-
flammation through antigen-dependent activation and
cytokine-dependent differentiation into functional T
cell subsets. T helper 17 (Th17) cells are unique pro-
inflammatory Th cells identified by retinoic acid
receptor-related orphan receptor gamma t (RORγt) and
interleukin-17 (IL-17) [2]. The IL-23/Th17/IL-17 path-
way plays an important role in regulating IBD, and
studies have found that Th17 levels are increased in
both the colonic mucosa and serum of IBD patients [3].
Other T cells that differentiate from Th cells include
regulatory T cells (CD4+CD25+FoxP3+ Treg), which play a
key role in modulating the immune response [4]. Tregs
are defined by the expression of both surface CD4+CD25+
and the intracellular transcription factor, FoxP3, which
plays a key role in regulating Treg activity [5]. Tregs regu-
late the homeostasis of the intestinal immune system by
promoting anti-inflammatory cytokine production, includ-
ing interleukin-10 (IL-10), and exerting dominant negative
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regulation of other T helper cells such as Th17 [6].
Tregs both produce and respond to TGF-β, an anti-
inflammatory cytokine that plays an important role in
maintaining Treg activity [7]. IL-6, an important signaling
protein for maintaining the Treg/Th17 balance, suppresses
Treg maturation and promotes a predominantly Th17
mediated pro-inflammatory response [8].
Short-chain fatty acids (SCFAs) are formed by bacterial
fermentation of non-starch polysaccharides (NSP), such
as dietary fiber in the colon [9]. Butyrate is mostly pro-
duced by Faecalibacterium prausnitzii (F. prausnitzii)
and serves as an energy source for colonocytes. It appears
to exert a promising anti-inflammatory effect by influen-
cing immune cell migration, cytokine expression, and
other cellular processes (eg. proliferation, activation and
apoptosis) [10]. Studies in UC patients have suggested that
both the administration of butyrate and the stimulation of
luminal butyrate production by the ingestion of dietary
fiber have an ameliorating effect on intestinal inflamma-
tion and related symptomology [11].
Although the administration of butyrate improves IBD-
related lesions and symptoms, the exact anti-inflammatory
mechanism remains unclear, and its impact on Treg/Th17
differentiation has not yet been examined. Therefore, the
hypothesis of this study is that the administration of
butyrate can ameliorate lesions and symptoms of colo-




Both patients and healthy participants were recruited by
the Affiliated Hospital of Nanjing University and exposed
to the same diet and living environment. None of the par-
ticipants used probiotics, antibiotics, or sulfasalazine in
the preceding two months. UC diagnosis was based on
clinical, endoscopic, and histological criteria, and UC dis-
ease activity was defined using the Simple Clinical Colitis
Activity Index (SCCAI) on the date of fecal sampling
[12]. The characteristics of all participants are shown in
Table 1.
Modeling of colorectal colitis in rats and treatment
The rats (Sprague–Dawley, 7 weeks, males) were induced
by TNBS administration [13]. Briefly, the TNBS (Sigma)
solution was slowly administered in the colon (100 mg/kg
body weight) via a 4.7 mm-diameter catheter. The control
was administered with vehicle. After TNBS-administration,
the rats were gavaged daily with sodium butyrate (Sigma)
solution (0.5 mM/kg body weight) for 20 consecutive days.
The control was administered with vehicle. The rats were
weighed at the indicated time and killed using ether expos-
ure at day 21. The colon specimens were stained with
hematoxylin and eosin, and lesions were analyzed using
the modified Neurath Scoring criteria [14] (briefly, 0 = no
inflammation; 1 = very low level of leucocyte infiltration;
2 = low level of leucocyte infiltration; 3 = high level of
leucocyte infiltration, high vascular density, thickening
of the colon wall; 4 = transmural leucocyte infiltrations,
loss of goblet cells, high vascular density, thickening of
the colon wall).
Short-chain fatty acids (SCFAs) assay
Fresh faecal samples were collected and stored in at −80 °C.
Faecal samples were mixed with water and centrifuged. The
supernatant was filtered and mixed with ether and sulfuric
acid. After high speed centrifugation, the ether layer was
collected and measured in the Agilent 6890 N Gas
Chromatograph Machine for SCFA concentrations.
Immunohistochemistry
Colon specimens were fixed in 4 % formalin and embedded
in paraffin. The sections were were incubated with rabbit
anti-rat IL17 antibodies (Abcam) and then treated with
immunoperoxidase using the DAB kit (Zsbio). Sections
were scored in a blind manner using a protocol modified
from Brown &Wahl [15].
Peripheral blood mononuclear cell (PBMC) culture
PBMCs were isolated from the venous blood of healthy
donors [16]. The cells were subsequently suspended in
complete medium (2 × 106 cells/ml) and seeded in a
24-well plate (2 × 106 cells/well). PBMCs were then
treated with PBS and different concentrations of so-
dium butyrate (Sigma), respectively, for 72 h in 24-well
plates pre-coated with UV-irradiated E. coli at a
PBMC:bacteria ratio of 1:10. After 72 h, the culture
supernatant from the PBMCs was collected and stored
Table 1 Characteristics of the study population
Characteristics Control (N = 10) UC (N = 7) p Value
Male/female (%) 5/5(50/50) 3/4(43/57) p > 0.05
Median (IQR) age (years) 47(31–50.5) 47(31–50.5) p > 0.05
Median (IQR) duration of
disease (years)
NA 5(2–6.5) NA
Median (IQR) BMI 25(23–26.5) 26(21–27) p > 0.05
Medication NA NA




Disease activity NA NA
Remission (SCCAI Score < 5) 3(43)
Active (SCCAI Score ≥ 5) 4(57)
Groups were compared by non-parametric analyses
BMI body mass index, NA not applicable
p < 0.05 was considered significant
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at −80 °C for cytokine analysis. PBMCs were used for
flow cytometry.
FCM (flow cytometry) analysis of Treg cells
Mononuclear cells were isolated from blood using Ficoll-
Isopaue density gradient centrifugation (Ficoll-Paque, MP
Biomedicals). FCM followed routine procedures, and cells
were labeled with FITC anti-CD4 (eBioscience), APC
anti-CD25 (eBioscience) and PE anti-Foxp3 (eBioscience).
Primary splenocyte culture
Untreated 7-week-old SD rats were sacrificed using
cervical dislocation following ether exposure. The sple-
nocytes were incubated with recombinant human
TGF-β (2 ng/ml, Peprotech) and recombinant rat IL-6
(20 ng/ml, Peprotech) at 37 °C for 72 h, whereas the
control was treated with vehicle. Experimental group cells
were treated with PBS or different concentrations of so-
dium butyrate (Sigma) in addition to TGF-β and IL-6 [17].
Primary splenocyte and bone marrow-derived dendritic
cell (BMDC) culture
Untreated 7-week-old SD rats were sacrificed using
cervical dislocation following ether exposure. The sple-
nocytes were incubated with recombinant human
TGF-β (2 ng/ml, Peprotech) and recombinant rat IL-6
(20 ng/ml, Peprotech) at 37 °C for 72 h [17]. Immature
BMDCs were isolated using a protocol modified from
Inaba et al. [18], in the presence of recombinant rat IL-4
(10 ng/ml, Peprotech) and recombinant rat granulocyte-
macrophage colony-stimulating factor (GM-CSF, 10 ng/ml,
Peprotech).
ELISA assay and western blotting
Cytokines (IL-10, IL-17A, IL-12 p70, TGF-β1, IL-6 and
IL-23) were measured using a commercially available
ELISA kit (Bender: IL-10, IL-17A, IL-12 p70 kits; SABC:
IL-23 kit; eBioscience: TGF-β1, IL-6 kits) according to
the manufacturer’s instructions. For western blotting, cells
were lysed using 0.5 % NP40 lysis buffer and proteins were
blotted following standard protocol. Antibodies to RORγt
(Abcam) and actin (GenScript Corp) were purchased
commercially.
Statistics
Data was expressed as the mean ± standard error of the
mean (SE). The data was analyzed with one-way ANOVA
followed by a post hoc Duncan test (SPSS 17.0). P < 0.05
was considered significant.
Results
Intestinal fatty acid levels
Ulcerative colitis patients had a net concentration of
butyric acid that was significantly lower than that of
healthy controls (Fig. 1a). Moreover, rats in the TNBS-
treated colitis group had significantly lower net concen-
trations of butyric acid and total SCFA concentrations
than did rats in the control group (Fig. 1b-c). Following
administration of sodium butyrate, fecal concentration
of butyric acid, total SCFA, and the percentage of butyric
acid were higher in the butyrate group than in the colitis
group (Fig. 1b-c).
Body weight, colon histology and blood cytokine
production
Rats in the TNBS-treated colitis group had significantly
smaller weight gain, as well as more severe inflammation
and higher colon Neurath scores than did rats in the
control group (Fig. 2a-c). Butyrate administration signifi-
cantly ameliorated the weight loss, increased colon in-
flammation, and higher Neurath scores observed in rats
within the colitis group (Fig. 2a-c). Butyrate-treated rats
only displayed mild mucosal and/or submucosal inflam-
mation with a relatively low level of neutrophil infiltration
Fig. 1 Intestinal fatty acid levels. Human fecal butyrate concentration
(a). Rat fecal butyric acid concentration and percentage of total SCFA
content (b). Rat fecal total SCFA content (c). Data are the mean ± SE.
n = 5–7. *P < 0.05; **P < 0.01; NS: No Significance. UC-R, remission
phase of ulcerative colitis; active phase of ulcerative colitis
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and mild edema (Fig. 2b). Plasma cytokines, such as IL-12,
IL-10 and the IL-10/IL-12 ratio, can be used to assess
systemic levels of inflammation [19]. Plasma levels of
IL-10 and the IL-10/IL-12 ratio were higher in the bu-
tyrate group than in the colitis group (Fig. 2d and f ),
but IL-12 levels were lower. The colonic cytokine results
were consistent with the plasma results.
Treg analysis in rats
In vivo studies demonstrated a significantly lower per-
centage of CD25 + Foxp3+ Tregs in the peripheral blood
of rats from the TNBS-treated colitis group than in the
control group (Fig. 3a and b). Following treatment with
butyrate, the percentage of CD25 + Foxp3+ Tregs in the
peripheral blood increased (Fig. 3a and b). With sufficient
IL-6, TGF-β can stimulate native T cells to differentiate
into Th17 cells [2]. However, without sufficient IL-6,
TGF-β stimulates native T cell differentiation into Tregs
[20]. As CD25 + Foxp3+ Treg frequencies increased
following butyrate treatment, we examined the level of
IL-6 and TGF-β in rat plasma. Plasma levels of IL-6 in
the colitis group were significantly higher than those in
the control group, which was consistent with the results
of the CD25 + Foxp3+ Treg analysis in rat peripheral
blood cells (Fig. 3c). Nonetheless, there was no significant
difference in TGF-β levels between the two groups
(Fig. 3d). Butyrate treatment, however, resulted in sig-
nificantly lower plasma levels of IL-6 (Fig. 3c) and signifi-
cantly higher levels of TGF-β (Fig. 3d) when compared to
the colitis group.
Th17 analysis of rats
IL-6 and TGF-β can stimulate native T cell differentiation
into Th17 cells, which in turn produce and secrete IL-17
Fig. 2 Body weight, colon histology and cytokines in rats. Body weight (a). Colon histology, upper and lower panel magnifications are × 40 and × 200,
respectively. Scale bars, 200 μm (b). Colon Neurath score (c). IL-10 of plasma and colon (d). IL-12 of plasma and colon (e). Plasma IL-10/IL-12 (f). Data
are the mean ± SE. n = 5–7. *P < 0.05; **P < 0.01
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Fig. 3 Treg analysis in rats. The percentage of CD4+CD25+Foxp3+ Tregs (a). Quantified CD4+CD25+Foxp3+ Tregs (b). Plasma IL-6 (c). Plasma TGF-β
(d). Data are the mean ± SE. n = 5–7. *P < 0.05; **P < 0.01
Fig. 4 Th17 analysis in rats. IL-17 immunohistochemical staining in the colon; upper and lower panel magnifications are × 40 and × 200, respectively.
Scale bars, 200 μm (a). Quantified IL-17 immunohistochemical staining in colon (b). Immunoblotting for RORγt in mesenteric lymph nodes, shown are
representative western blot results of three rats (c). Plasma IL-17 (d). Plasma IL-23 (e). n = 5–7. Data are the mean ± SE. n = 7. *P < 0.05; **P < 0.01
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[2]. Th17 cells are identified by RORγt and IL-17, and
IL-17 is detectable in both plasma and colon tissue in
rats. IL-17 levels were found to be greater in the colitis
group than in the control group, and decreased follow-
ing butyrate treatment (Fig. 4a-b and d). Accordingly,
butyrate treatment also decreased the colitis related
RORγt increase in mesenteric lymph node (MLN)
(Fig. 4c). IL-23 acts as an upstream regulator of Th17
cells and is critical for maintaining the stability and activa-
tion of Th17 cells [3]. Plasma IL-23 levels were increased
in the colitis group, and likewise decreased following
butyrate treatment (Fig. 4e).
Treg and Th17 cell differentiation in vitro
We performed in vitro Treg Th17 analysis using human
PBMCs in order to verify the in vivo experiments. The
in vitro studies demonstrated that the CD4+CD25+Foxp3+
subpopulation in the PBMCs was consistently up-
regulated by butyrate treatment in a dose-dependent
manner (Fig. 5a-b). IL-6 and TGF-β can stimulate native
T cell differentiation into Th17 cells [2] and immature
bone marrow dendritic cells (BMDCs) can be activated by
lipopolysaccharide (LPS) from E.coli to secrete IL-23,
which plays an important role in maintaining the stability
and function of Th17 cells [21]. In vitro, IL-6 and TGF-β
treatment significantly increased IL-17 and RORγt levels
from rat splenocytes, especially in comparison to the
non-stimulated control group (Fig. 6a). Moreover, IL-17
and RORγt levels were significantly lower in cells cultured
with butyrate in a dose-dependent manner than in the
PBS group (Fig. 6a). In vitro, UV-irradiated E.coli caused a
significant increase in IL-23 secretion in the immature
BMDCs in comparison to the non-stimulated control
group (Fig. 6c). Additionally, IL-23 secretion was signifi-
cantly lower in cells cultured with 80 μM butyrate than in
the PBS group (Fig. 6c). UV-irradiated E.coli in the PBS
group further caused a significantly increase in IL-17
and RORγt levels when splenocytes and BMDCs were
co-cultured (Fig. 6b). UV-irradiated E. coli -treated cells
incubated with 80 μM butyrate expressed significantly
less IL-17 and RORγt levels (Fig. 6b).
Discussion
The major finding in this study was that butyrate exerted
potent effects that ameliorated colitis lesions in a rat
model by influencing Th cell differentiation and activation.
This study proposes several possible mechanisms for these
effects, including: 1) the inhibition of inflammatory Th17
cell activation and cytokine (IL-17) release, 2) the promo-
tion of Treg cell differentiation and 3) alterations in the
ratio in inflammatory cytokines (i.e., IL-10/IL-12) released
by monocytes.
Firmicutes is a well-known butyrate-producing bacter-
ium and several studies have confirmed that a reduction
in F. prausnitzii and its product in IBD patients is in-
versely correlated with disease scores [22, 23]. Butyrate-
producing microbiotic pharmabiotics have been shown
to be effective in TNBS models and are destined for clin-
ical trials [24]. Consistent with previous research in col-
itis models, our study confirmed that UC patients had
Fig. 5 Treg cell differentiation in vitro. The percentage of CD4+CD25+Foxp3+ Tregs (a). Quantified CD4+CD25+Foxp3+ Tregs (b). Culture supernatant
IL-6 (c). Culture supernatant TGF-β (d). Data are the mean ± SE. n = 4. *P < 0.05; **P < 0.01. But40, 40 μM sodium butyrate. But80, 80 μM
sodium butyrate
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lower fecal butyrate concentrations than did the control
group. Our study utilized butyrate concentrations rec-
ommended by Di Sabatino et al. [25] and found that oral
administration of butyrate resulted in increased percent-
age of butyric acid, fecal concentration of butyric acid,
and total SCFA. This resulted in improved health status,
including increased weight gain, lower colonic inflam-
mation, and lower Neurath scores in the butyrate group
rats as compared to the colitis group. These results were
further confirmed by cytokine testing.
Th17 cells are a unique proinflammatory Th cell sub-
set identified by RORγt and IL-17. Since the discovery
of Th17, a number of studies have suggested that the
IL-23/Th17/IL-17 pathway plays an important role in
nearly all major autoimmune syndromes including IBD
[3]. Studies have found that IL-17 levels are increased
in both the colonic mucosa and serum of IBD patients,
and IL-17 blocking therapy is being tested in patients
with IBD [26, 27]. Serum concentration of total SCFAs in
rodents is around 0.1 ~ 1 mM, among which only 10 %
are butyrate [28, 29]. Therefore, the serum concentration
of butyrate is estimated to be approximately 100 μM at
most. Under physiological concentration of butyrate, we
found that the high levels of RORγt and IL-17 caused by
TNBS were both significantly reduced by butyrate treat-
ment, suggesting their protective nature in the onset of
colitis. IL-6 signaling is required for Th17 cell lineage
commitment and its differentiation is enforced by TGF-β
[2]. IL-23 is an essential upstream regulator of Th17 cells
that maintains Th17 activity and function, and immature
bone marrow dendritic cells (BMDCs) can be activated
by lipopolysaccharide (LPS) from E.coli to secrete IL-23
[3, 21]. Our study found that plasma levels of IL-23 and
IL-6 were significantly increased by TNBS treatment
Fig. 6 Th17 cell differentiation in vitro. IL-17 release from rat splenocytes (left) and immunoblotting for RORγt in rat splenocytes (right) in vitro (a).
IL-17 release from co-cultured BMDCs and splenocytes (left) and immunoblotting for RORγt in co-cultured BMDCs and splenocytes (right) in vitro
(b). IL-23 released from the BMDCs with UV-irradiated E. coli stimulation (c). Data are the mean ± SE. n = 4. *P < 0.05; **P < 0.01. But40, 40 μM
sodium butyrate. But80, 80 μM sodium butyrate
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and reduced by butyrate administration. This suggests
that the IL-23/Th17/IL-17 pathway is an effective target
for butyrate treatment in the setting of inflammatory
colitis. Our in vitro experiments in rat splenocytes and
BMDCs further confirmed this in vivo data. When spleno-
cytes differentiated into Th17 cells in vitro, we demon-
strated a similar cytokine release profile to that observed
in colitis rats. Only a high dose of butyrate (80 μM) could
suppress the secretion of IL-23 by BMDCs and the secre-
tion of IL-17 by the splenocytes when co-cultured with
BMDCs. Consistent with IL-17 levels from cultured sple-
nocytes, RORγt levels in splenocytes also decreased fol-
lowing butyrate treatment. Taken together, this suggests
that butyrate inhibits Th17 differentiation.
Regulatory T cells (Treg) also differentiate from Th
cells in presence of TGF-β [4]. Tregs maintain homeo-
stasis by producing anti-inflammatory cytokines such as
IL-10 and exert important negative regulation of Th17
cells. Impaired function of IL-10 and the IL-10 receptor
are associated with aggressive IBD [6]. The insufficiency
of Tregs in germ-free mice can be restored via a high-
fiber diet induced by butyrate in vivo. This is corrobo-
rated by in vitro studies demonstrating that microbes
producing butyrate stimulate the differentiation of Tregs
and exert anti-inflammatory activity in the intestinal
mucosa of a mouse model [30, 31]. Consistent with pre-
vious results, our in vivo study demonstrated butyrate
treatment increased both the percentage of Treg and the
levels of IL-10, suggesting that the protective effect of
butyrate on intestinal inflammation was correlated with
the level of IL-10. TGF-β, together with IL-6, can stimu-
late native T cells to differentiate into Th17 cells [2]. Yet
without sufficient IL-6, TGF-β stimulates native T cells
differentiation into Tregs [20]. Increased levels of Tregs
in rat peripheral blood cells were found in combination
with increased plasma levels of TGF-β, whereas butyrate
treatment decreased IL-6 levels. The in vitro experiments
in human PBMCs further confirmed this in vivo data. A
high dosage of butyrate (80 μM) could promote secretion
of TGF-β by PBMCs and increased Treg frequencies in
PBMCs.
Conclusions
In summary, a fine balance exists between Treg and
Th17 cells in a healthy state. The same Th cell pool that
generates Treg is also capable of producing Th17 cells,
and this is coordinated by cytokines including IL-10,
TGF-β and IL-6. Our results suggest that butyrate, a
well-known metabolite, played a key role in regulating
this Treg/Th17 balance and in turn yielded important
insights for the treatment of IBD.
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